O-(4-ethoxybutyl)berbamine: structure given in first source; calmodulin antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 188375 |
| CHEMBL ID | 454806 |
| MeSH ID | M0143901 |
| Synonym |
|---|
| 106006-09-1 |
| o-(4-ethoxybutyl)berbamine |
| CHEMBL454806 , |
| berbaman, 12-(4-ethoxybutoxy)-6,6',7-trimethoxy-2,2'-dimethyl- |
| bdbm50293304 |
| o-(4-ethoxybutyl)-berbamine |
| 0-4-(ethoxybutyl)berbamine |
| o-4-(ethoxybutyl)berbamine |
| DTXSID40909866 |
| 12-(4-ethoxybutoxy)-6,6',7-trimethoxy-2,2'-dimethylberbaman |
| (1s,14r)-9-(4-ethoxybutoxy)-20,21,25-trimethoxy-15,30-dimethyl-7,23-dioxa-15,30-diazaheptacyclo[22.6.2.23,6.18,12.114,18.027,31.022,33]hexatriaconta-3(36),4,6(35),8,10,12(34),18,20,22(33),24,26,31-dodecaene |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The MTT method was used to analyze the effect of Dox or PLD alone, Dox in combination with EBB, or PLD in combination with EBB on the growth of H(22) cells in an in vitro experiment." | ( Effect of O-4-ethoxyl-butyl-berbamine in combination with pegylated liposomal doxorubicin on advanced hepatoma in mice. Fang, BJ; Liao, LM; Liu, JW; Yang, SG; Yu, ML; Zhao, RC, 2004) | 0.32 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | IC50 (µMol) | 0.3500 | 0.0002 | 1.5574 | 10.0000 | AID397126 |
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A | Homo sapiens (human) | IC50 (µMol) | 0.3500 | 0.2300 | 2.5105 | 10.0000 | AID397126 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| photoreceptor outer segment | Prostaglandin G/H synthase 1 | Homo sapiens (human) |
| cytoplasm | Prostaglandin G/H synthase 1 | Homo sapiens (human) |
| endoplasmic reticulum membrane | Prostaglandin G/H synthase 1 | Homo sapiens (human) |
| Golgi apparatus | Prostaglandin G/H synthase 1 | Homo sapiens (human) |
| intracellular membrane-bounded organelle | Prostaglandin G/H synthase 1 | Homo sapiens (human) |
| extracellular exosome | Prostaglandin G/H synthase 1 | Homo sapiens (human) |
| cytoplasm | Prostaglandin G/H synthase 1 | Homo sapiens (human) |
| neuron projection | Prostaglandin G/H synthase 1 | Homo sapiens (human) |
| cytosol | Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A | Homo sapiens (human) |
| neuronal cell body | Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID397126 | Inhibition of calmodulin-dependent phosphodiesterase | |||
| AID397139 | Inhibition of calmodulin-stimulated Ca2+/Mg2+ ATPase activity in human erythrocyte membrane | |||
| AID429101 | Cytotoxicity against human imatinib-resistant K562 leukemia cells expressing p210Bcr/Abl and MDR1 at 48 hrs by MTT assay | 2009 | European journal of medicinal chemistry, Aug, Volume: 44, Issue:8 | Berbamine derivatives: a novel class of compounds for anti-leukemia activity. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (22.22) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.59) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (10.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (90.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||